Press release
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
- GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) -\n\n- GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) -\n\n- GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer Meeting 2020 - \n\n- GB001: Engaging with global regulatory authorities about forward clinical development path for an oral DP2 antagonist in moderate-to-severe asthma -\n\n- Cash, cash equivalents and marketable securities totaled $555 million as of September 30, 2020 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the third quarter of 2020 and provided a corporate update.\n\n“We are very excited about the continued advancement of our pipeline with the start of two robust Phase 2 clinical trials for GB002 and GB004 and the planned dose expansion cohort for GB1275,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We believe that these clinical programs hold tremendous potential to benefit high unmet need patient populations.”\n\nClinical-Stage Product Candidate Updates\n\nGB002: Inhaled PDGFR Inhibitor for Pulmonary Arterial Hypertension (PAH)\n\n\nGB002 is currently being evaluated in an ongoing Phase 1b trial in PAH. Gossamer will discuss the initial results from this ongoing trial at as part of a GB002-focused investor webinar in December 2020.\n\n\n\nSites activated in the TORREY Study, a 24-week Phase 2 clinical trial in functional class II and III PAH patients. Gossamer expects to begin enrollment for this trial in the fourth quarter of 2020. The primary endpoint is change in pulmonary vascular resistance (PVR) from baseline at week 24. Topline data from the TORREY study are expected in the first half of 2022, subject to developments in the ongoing COVID-19 pandemic.\n\n\nGB004: Oral HIF-1α Stabilizer for Inflammatory Bowel Disease\n\n\nSeveral patients dosed in the SHIFT-UC Study, a Phase 2 clinical trial in UC patients. The primary endpoint is proportion of patients with clinical remission at week 12...